ArticleSeminars in arthritis and rheumatism2026
Multimorbidity and risk of infection in patients with rheumatoid arthritis: Population-based case-control study.
Article in Seminars in arthritis and rheumatism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vaccination considerations in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePatients with rheumatoid arthritis (RA) have elevated infection risk owing to disease- and treatment-related immune dysfunction. Whether multimorbidity adds risk remains uncertain. This study evaluated the association between multimorbidity and infection in RA.
methodsA nationwide nested case-control study was conducted in Korea using the Health Insurance Review and Assessment Service database mapped to the Observational Medical Outcomes Partnership Common Data Model. RA was identified by the International Classification of Diseases, 10th revision (M05-M06) with same-day disease-modifying antirheumatic drug prescriptions in 2018-2019. Patients with major immunodeficiencies or recent infections were excluded. Cases were the first serious, opportunistic, or herpes zoster infections between January 1, 2020, and April 30, 2022. Four controls were matched to each case by age, sex, and seropositivity. Multimorbidity was assessed using chronic conditions present during the 2 years preceding infection.
resultsCompared with patients with <10 conditions, those with RA and ≥10 conditions had higher odds of infection. A dose-response pattern was evident across multimorbidity groups. Adjusted odds ratios were 1.44 (95% confidence interval 1.32-1.58) for serious infection, 2.19 (1.06-4.53) for opportunistic infection, and 1.18 (1.05-1.34) for herpes zoster. Associations were consistent across subgroups. Multimorbidity increased nonfatal but not fatal infections. Among major infection types, only complicated skin and soft tissue infections were significant.
conclusionIn Korean adults with RA, multimorbidity substantially increases infection risk in a dose-response manner, particularly for cutaneous and nonfatal infections. These results highlight the cumulative impact of chronic conditions and support holistic management with proactive infection monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.